Interpace Q2 2026: revenue $9.1M, income $0.3M vs prior loss; thyroid revenue +9% YoY

INTERPACE BIOSCIENCES, INC.

2026-Q2 EPS reported $0.03 revenue$18,163,000

Q2 revenue $9.1M, up 9% Pro Forma (ex-PancraGEN); income from continuing ops $0.3M vs $0.5M loss prior year.
Thyroid revenue +9% YoY, volume +6%; TTM thyroid revenue $36.1M, up 11%; gross margin 62% vs 54% Pro Forma.
Adjusted EBITDA $0.7M (8% margin) vs $0.2M Pro Forma prior year; includes $0.2M one-time strategic fees.
H1 2026 income $1.1M vs $0.2M loss Pro Forma; Adjusted EBITDA $2.3M (13% margin); debt-free balance sheet.
Adding Chief Scientific Officer Sept 8, 2026; pancreatic cancer program in development, no revenue expected in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.